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A B S T R A C T
Interleukin-1β (IL-1β) is a pleiotropic cytokine that exerts multiple roles in both physiological and pathological
conditions. It is produced by different cell subsets, and drives a wide range of inflammatory responses in
numerous target cells. Enhanced IL-1β signaling is a common event in patients of hematological malignancies.
Recent body of evidence obtained in preclinical models shows the pathogenic role of these alterations, and the
promising therapeutic value of IL-1 targeting. In this review, we further highlight a potential contribution of IL-
1β linking to complications and autoimmune disease that should be investigated in future studies. Hence, drugs
that target IL-1 may be helpful to improve outcome or reduce morbidity in patients. Some of them are FDA-
approved, and used efficiently against autoimmune diseases, like IL-1 receptor antagonist. In the clinic, however,
this agent seems to have limited properties. Current improved drugs will allow to determine the true potential of
IL-1 and IL-1β targeting as therapy in hematological malignancies and their related complications.
1. Introduction
Inflammation is a refined immune mechanism essential to fight
against pathogens and tumor cells, and orchestrated by a variety of cells
and mediators. When dysregulated, compiled data supports the hypoth-
esis that chronic inflammation promotes cancer. This is particularly
evident in hematological malignancies. Strikingly, a Swedish epidemio-
logical study found that history of any infectious disease was associated
with a 1.3-fold significantly increased risk of both acute myeloid
leukemia (AML) or myelodysplastic syndrome (MDS), even when
infection had occurred 3 or more years before AML or MDS onset. By
using population-based central registries, a total of 9219 patients with
primary AML (diagnosed from January 1, 1965, through December 31,
2004) and 1662 patients with primary MDS (diagnosed from January 1,
1993, through December 31, 2004), as well as 36,389 and 6489
population-based controls, respectively, were included. Further, to
minimise bias, patients diagnosed with another cancer before their
AML or MDS were excluded. Men represented 52.8% of the patients
with AML and 54.9% of MDS patients, and the median ages at diagnoses
were 68 and 76 years for AML and MDS, respectively. Interestingly,
although history of any infectious disease was associated to similar
increased risk of both AML and MDS, fewer individual subgroups of
infections were associated to MDS. A broad range of infections were
associated to AML including pneumonia, tuberculosis, intestinal infec-
tions, septicemia, hepatitis C, pyelonephritis, sinusitis, nasopharyngitis,
upper respiratory tract infection, cytomegalovirus infection, and cellu-
litis [1]. One plausible explanation of these data is that chronic immune
stimulation may act as trigger for AML and MDS development.
Chronic inflammation and autoimmune conditions have been con-
sistently linked with increased risk of malignant lymphomas, with
varying risk levels [2]. More recently, in patients of myeloproliferative
neoplasms (MPN), chronic inflammation has been evidenced as poten-
tial initiating event and driver of clonal expansion that predisposes to
second cancer [3–5]. Interestingly, another Swedish large population-
based study found that patients with prior history of autoimmune
disease had 20% increased risk of MPN development. In total, 11,039
MPN patients (diagnosed from 1958 to 2005) were included together
with 43,550 matched controls. Men represented 48.4% of MPN
patients, and the mean age at diagnosis was 67 years. A total of 288
(2.6%) MPN patients had a previous history of autoimmune disease.
Higher risk of MPN was associated with prior thrombocytopenic
purpura, Crohn's disease, polymyalgia rheumatic, giant cell arteritis,
Reiter's syndrome and aplastic anemia [6]. High basal inflammatory
status seems to promote mutagenesis through induction of chronic
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oxidative stress and subsequent DNA oxidative damage, and elicits
epigenetic changes that further promote inflammation [3]. In addition,
the MPN population has a significant inflammation-mediated comor-
bidity burden, ranging from second cancer to cardiovascular and
thromboembolic disease, chronic kidney disease, autoimmune disease
and osteopenia [7].
One of the cytokine families most related to innate immune
responses and inflammation is the IL-1 family. It comprises 11 members
(Table 1) with agonist activity, receptor antagonists and an anti-
inflammatory cytokine, for a tight control of inflammatory responses
[8]. IL-1α, IL-1β, IL-1 receptor antagonist (IL-1Ra) and IL-18 have been
extensively studied in vitro, animal models of disease and humans [9].
Among these, IL-1β stands out as initiator of inflammatory processes,
and blocking its activity in humans is currently applied in clinical
treatments. This review presents the pathogenic role of dysregulated IL-
1β in patients of hematological malignancies, its promising therapeutic
value in preclinical models, and its potential contribution linking to
second disease and complications based on lessons learned from other
systemic inflammatory diseases.
2. Physiological characteristics of IL-1β and role in the
hematopoietic system
IL-1β is mainly produced by myeloid cells [10,11]. It is synthesized
as an inactive form (Fig. 1A), pro-IL-1β that is activated intracellularly
by caspase 1 [8,11]. Under normal conditions, IL-1β is secreted in low
levels, and its expression and/or caspase 1-mediated activation in-
creases under disease [12,13]. In autoinflammatory diseases, high IL-1β
tissue levels are usually accompanied by an increase in blood levels
given that monocytes release more processed IL-1β [9,14–17]. Secreted
IL-1β binds to its IL-1 receptor 1 (IL-1R1) and triggers a signaling
cascade that controls gene expression of multiple transcription factors,
growth factors and other interleukins involved in hematological func-
tion (Fig. 1B) [10]. Thereby, IL-1β plays an important role in innate and
adaptive immune cellular responses. It stimulates maturation of T cells
and enhances proliferation of B cells [18–20]. Further, IL-1β promotes
expression of inflammatory molecules such as cyclooxygenase type 2,
type 2 phospholipase A, prostaglandin E2, platelet activating factor and
nitric oxide [9], among others.
Importantly, IL-1β modulates hematopoietic stem cell (HSC) func-
tion. In preclinical models, it promotes HSC differentiation biased into
the myeloid linage, in part through activation of PU-1 signaling
(Fig. 2A) [21]. While acute IL-1β exposure contributes to HSC
regeneration after myeloablation and transplantation [21,22], chronic
exposure promotes uncontrolled HSC division and eventual exhaustion
of the HSC pool [21]. Several studies have shown neutrophilia,
leukocytosis and thrombocytosis following IL-1β treatment [12,23].
In contrast, inhibition of IL-1β signaling using IL-1Ra, which competi-
tively binds to IL-1R1 and prevents binding of the cytokine (Fig. 1B)
[24], reduces colony formation ex vivo [25,26]. In vivo, IL-1Ra
suppresses cell cycle in bone marrow HSC, and reduces numbers of
leukocytes and platelets [26]. Thus, preclinical models show that fine-
tuned IL-1β levels play a physiological role in hematopoiesis, and
suggest that their dysregulation may participate in hematological
diseases [10,21,27].
3. IL-1β in clinical and preclinical models of hematological
malignancies: emerging therapeutic implications
3.1. MPN
MPN are a group of clonal HSC disorders characterized by increased
proliferation of at least one of the following lineages; eythroid,
megakaryocytic and myeloid, and retaining full differentiation [28].
Underlying chronic inflammation has been suggested to contribute to
disease initiation and/or progression [3]. Classical Philadelphia chro-
mosome negative (negative for BCR-ABL gene fusion) MPN includes
mainly essential thrombocythemia (ET), polycythemia vera (PV) and
primary myelofibrosis (PMF) (Table 2 [29]). Most frequent BCR-ABL
negative MPN are associated with Janus kinase 2 (JAK2), calreticulin
and myeloproliferative leukemia virus oncogene (MPL) mutations,
among others [28,30].
MPN patients show increased levels of inflammatory cytokines in
serum [31,32], and gene expression profiling and functional annotation
analysis confirms deregulation of inflammatory and immune system
genes [33]. Pro-inflammatory cytokines have traditionally been related
to initiation and progression of bone marrow myelofibrosis at advanced
stages of disease [34]. Unlike PV or ET patients [35–37], PMF patients
show high levels of IL-1β together with other pro-inflammatory
cytokines and growth factors in plasma [35,37]. If high IL-1β levels
are present in PV patients, those are correlated to fibrotic transforma-
tion, poor prognosis and lower survival [37].
Mastocytosis is a less common form of myeloid neoplasm character-
ized by mast cell expansion in bone marrow and other organs [27]. It
has been separated from other MPNs in the 2016 revision to the WHO
classification of myeloid neoplasms and acute leukemia due to its
unique clinical and pathological characteristics, ranging from indolent
cutaneous disease to aggressive systemic disease (Table 2 [29]).
Aggressive phenotypes of mastocytosis are related to up-regulation of
IL-1β in mast cells [38].
Our recent work has shed light on the pathogenic role of IL-1β in
preclinical models of MPN. Using a transgenic mouse model that
expresses the human mutant JAK2-V617F under the endogenous
promoter of Jak2 in an inducible way, we showed that IL-1β produced
at early stages of disease, at least in part by mutant HSCs, induces
damage of the neuroglial components in the bone marrow. Reduced
sympathetic regulation together with IL-1β stimulation results in
mesenchymal stem cell (MSC) apoptosis that then allows expansion of
mutant HSCs (Fig. 2B) [39]. The pathogenic role of IL-1β was
uncovered by administration of IL-1Ra, which ameliorates hallmarks
of disease, recovers MSC numbers in vivo and prevents apoptosis of glial
cells ex vivo (Table 3) [39]. These data suggest that targeting IL-1β may
have clinical implications to improve treatment of MPN patients.
3.2. Chronic myeloid leukemia (CML)
BCR-ABL or Philadelphia positive CML is classified as an MPN
disorder, but it is usually considered as a separate entity because of its
unique features and responses to treatment (Table 2 [29]) [28]. CML is
a biphasic disease characterized by excessive expansion of the granu-
locytic lineage during the initial chronic phase. Acquisition of addi-
tional genetic and/or epigenetic abnormalities causes the progression to
blast phase, which characterizes by a block of cell differentiation that
results in presence of 30% or more myeloid or lymphoid blast cells in
peripheral blood or bone marrow, or presence of extramedullary
infiltrates of blast cells [40].
High levels of IL-1β are associated with poor prognosis in CML
Table 1
IL-1 family member nomenclatures and main activity.
Family member Alternative name Function
IL-1α IL-1F1 Inflammatory
IL-1β IL-1F2 Inflammatory






IL-36Ra IL-1F5 Anti-inflammatory (Receptor antagonist)
IL-37 IL-1F7 Anti-inflammatory
IL-38 IL-1F10 Anti-inflammatory (Receptor antagonist)
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[41,42]. Increased IL-1β is seen in advanced blast phase as compared to
chronic phase and healthy controls, and correlates with blast expansion
in bone marrow and peripheral blood, poor prognosis and shorter
survival in patients [41,43]. IL-1β stimulates proliferation of mutant
long-term HSC ex vivo, at concentrations comparable to those observed
in CML bone marrow [44], and helps promote colony growth of mutant
hematopoietic progenitors [45]. Use of IL-1Ra or soluble IL-1 receptor
suppressed this effect, suggesting that IL-1β could confer a proliferative
advantage to leukemic stem cells (LSC) [45]. Interestingly, IL-1 receptor
accessory protein (IL-1RAP) that is a required component of the IL-1R
complex (Fig. 1B), is highly expressed in BCR-ABL+ CML cells [46]. In
particular, IL-1RAP is up-regulated in CD34+ and CD34+ CD38- cells
from CML patients compared to controls, and its expression increases
with disease progression [47]. Further, anti-IL1RAP antibody targets
CML CD34+ CD38- cells via antibody-dependent cell-mediated cyto-
toxicity [46]. Hence, alterations in several components of the pathway
leading to strengthened IL-1 signaling may contribute to disease.
CML patients may display relapses through mechanisms dependent
on BCR-ABL [48,49] or through additional mutations, like those in
genes promoting HSC survival or multidrug resistance [50–52]. Im-
portantly, IL-1β contributes to resistance to BCR-ABL tyrosine kinase
inhibitor imatinib in CML cells, where it increases cell survival and
decreases apoptosis rate through cyclooxygenase 2 [53]. Interferon
(IFN) family members, alternative treatment against CML, have anti-
inflammatory effects and inhibit IL-1β [54–57]. Higher levels of IL-1β
were seen in IFN-α-resistant CML patients as compared to sensitive
patients and healthy controls, and IL-1β stimulates colony growth in
IFN-α-sensitive CML cells [45].
In mouse models of disease, IL-1Ra in combination with nilotinib,
drug with greater power and selectivity for BCR-ABL than imatinib
[58,59], reduces numbers of leukemic cells in blood and bone marrow,
and the self-renewal potential of leukemic stem cells (LSC). This
correlates with extended survival after completion of treatment com-
pared to mice treated with nilotinib alone (Table 3) [60]. In vitro, this
combination significantly reduced human CML progenitor cell growth,
including CD34+ CD38+ and CD34+ CD38- cells [61]. Then, block-
ade of IL-1 signaling together with BCR-ABL tyrosine kinase inhibition































Fig. 1. Interleukin-1β initiates inflammation and controls essential cell responses. A) Several external inflammatory stimuli that signal through TLR, activate a cascade of events that
culminate in activation of the transcription factor NF-κB. Following NF-κB activation, IL-1β is synthesized as its inactive form, pro-IL-1β, which is activated by cleavage through caspase 1.
Pro-caspase 1 is synthesized and activated in response to similar stimuli. B) Secreted IL-1β binds to its IL-1R1 and triggers a signaling cascade, which involves p38 MAPK, JNK, ERK and
NF-κB activation that control gene expression of multiple transcription factors, growth factors and interleukins involved in cell functional activation, survival responses and cell fate.
Under normal conditions, IL-1β signaling is negatively regulated through IL-1Ra, IL-1R2 and SIGIRR. LPS, lipopolysaccharide; TLR, toll-like receptors; NF-κB, nuclear factor kappa-light-
chain-enhancer of activated B cells; IL, interleukin; Casp1, caspase 1; IL-1Ra, IL-1 receptor antagonist; IL-1R, IL-1 receptor; IL-1RAP, IL-1 receptor accessory protein; TIR, toll-IL-1
receptor; SIGIRR; single immunoglobulin and TIR domain containing; MYD88, myeloid differentiation primary response 88; IRAK4, IL-1 receptor associated kinase 4; MAPK, mitogen-
activated protein kinases; JNK, c-Jun N-terminal kinases; ERK, extracellular signal-regulated kinases; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; TGF-β,
transforming growth factor β.
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3.3. Juvenile myelomonocytic leukemia (JMML)
JMML is a childhood MDS/MPN (Table 2 [29]) that may arise as
consequence of germline activating mutations of the protein tyrosine
phosphatase SHP2, encoded by the gene PTPN11 [62,63]. Interestingly,
both cell-autonomous [64] as well as Ptpn11 activating mutations in the
bone marrow microenvironment [65] promote development and pro-
gression of JMML. In mouse models of disease, Ptpn11 activating
mutations in MSCs and progenitor cells as well as in osteoprogenitors
cause increased secretion of the chemokine (C-C motif) ligand 3 (CCL3)
or macrophage inflammatory protein 1α (MIP-1α). CCL3 recruits
monocytes to the bone marrow microenvironment where HSCs reside.
Recruited monocytes produce IL-1β, and this in turn hyperactivates
HSCs leading to JMML (Fig. 2C). Interestingly, treatment with CLL3
receptor antagonists reverses JMML originated by the mutated micro-
environment (Table 3) [65]. However, it remains to be seen how
broadly applicable this mechanism will be, given that no human cases
were examined for presence of PTPN11 activating mutations particu-
larly in the bone marrow microenvironment. Further, from 4 patients
examined positive for PTPN11 activating mutations and with Noonan
syndrome, which predisposes to JMML, MSCs and progenitor cells
showed in culture varying levels of CLL3.
3.4. AML
AML is a heterogeneous disease characterized by aberrant myeloid
lineage proliferation and differentiation, and at least one clonal somatic
abnormality on mutational profiling in the majority of the patients
(> 97%) [66] (Table 2 [29]). IL-1β is produced by human AML blasts,
where its expression relates to poor patient prognosis [67,68]. Both
endogenous and exogenous IL-1β promote blast proliferation, by
induction of growth factors and other cytokines like granulocyte-
macrophage colony stimulating factor [69–74]. Poorer patient prog-
nosis and lower survival is observed in those patients with higher
proliferative response to exogenous IL-1β [75]. Further, IL-1β direct
inhibition or indirect inhibition targeting IL-1RAP, blocks colony
formation and proliferation of AML cells [76,77]. Endogenous IL-1
has also been related to apoptosis resistance in human AML, and
addition of recombinant human IL-1 in culture enhances cell survival
through pathways like phosphoinositide-3 kinase and ceramidase [78].
In addition, IL-1β secreted by human AML blasts, stimulates expression
of adhesion molecules that promote their recruitment by epithelial cells
[79], effect that may be relevant for tissue infiltration and metastasis.
In spite of these studies, the role of IL-1β in human AML remains
controversial. According to Su et al. [80], lower levels of IL-1β are
present in the plasma of AML patients compared to healthy controls.
Further, CD34+ CD38- progenitors, enriched within the LSC subset,
down-regulate IL-1β expression through epigenetic mechanisms, com-
pared with more mature CD34+ CD38+ AML progenitors and normal
CD34+ cells [81]. Forced expression of IL-1β stimulates cell cycle and
apoptosis in CD34+ CD38- AML progenitors, by down-regulation of
cyclin-dependent kinase inhibitor 1 (p21waf1) and antiapoptotic pro-
teins respectively. Similarly, over-expression of IL-1β in CD34+ CD38-
cells, reduces engraftment and reconstitution after transplantation into
B) MPN (JAK2-V617)















































Fig. 2. Pathological mechanisms of IL-1β on hematopoietic stem cell function identified in mouse models. A) Upon injury or infection, IL-1 is produced at high levels in the bone marrow
by monocytes and endothelial cells, among others. IL-1 drives myeloid differentiation through activation of the NF-κB pathway and a PU.1-dependent myeloid gene program that results
in HSC expansion, biased differentiation into myeloid progenitors and ultimately myeloid cells [21]. B) In a mouse model of MPN that expresses the human mutant JAK2-V617F, IL-1β is
produced at early stages of disease by mutant HSCs, and induces damage of the neuroglial components in the bone marrow. Reduced neural regulation together with enhanced IL-1β
results in mesenchymal stem cell apoptosis that then allows expansion of mutant HSCs [39]. C) In a mouse model of JMML that results from Ptpn11 activating mutation in MSCs and
progenitor cells, and in osteoprogenitors, increased levels of CCL3 recruits monocytes to the bone marrow. These produce IL-1β that promotes HSC expansion [65]. D) In normal HSCs, IL-
1β signaling through IL-1R1 drives UBE2O phosphorylation mediated by IRAK4. This increases UBE2O interaction with MLL and its degradation. In contrast, in a mouse model of AML
that results from expression of MLL-AF9 fusion protein, MLL chimeras are resistant to degradation driven by IL-1β [86]. IL-1β, interleukin-1β; HSC, hematopoietic stem cell; NF-κB,
nuclear factor kappa-light-chain-enhancer of activated B cells; PU.1, purine-rich nucleic acid binding protein 1; MPN, myeloproliferative neoplasm; JAK2, Janus kinase 2; MSC,
mesenchymal stem cell; CXCL12, C-X-C motif chemokine ligand 12; JMML, juvenile myelomonocytic leukemia; Ptpn11, tyrosine-protein phosphatase non-receptor type 11; MSPCs,
mesenchymal stem and progenitor cells; CCL3, C-C motif chemokine ligand 3; AML, acute myeloid leukemia; MLL, mixed-lineage leukemia gene; IRAK4, interleukin-1 receptor associated
kinase 4; UBE2O, ubiquitin conjugating enzyme E2 O.
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immunodeficient mice [82]. Interestingly, in the same study, the
authors showed that low dose IL-1β exposure stimulates colony
formation in AML cells, while high doses promote the opposite effect
[82]. This highlights the importance of balanced levels of IL-1β in AML,
where future studies are required aiming at understanding the specific
role played by IL-1β.
It is important to note that IL-1βmay be produced by certain subsets
of non-hematopoietic cells, like some stromal components of the
hematopoietic stem cell niche that supports HSC function. In normal
conditions, IL-1β at levels similar to those found in human serum,
stimulates MSC proliferation in vitro and their capacity to maintain
hematopoietic progenitor cells [83]. Bone marrow stromal cells from
healthy controls co-cultured with different leukemia cell lines, show an
up-regulation of IL-1β [84]. However, MSC from AML patients show
lower expression of IL-1β at the time of diagnosis, previous to bone
marrow transplantation and at least 6 months after the transplant,
compared to healthy controls [85].
Recently, preclinical models of AML have pinpointed IL-1 as a
potential therapeutic strategy. Using mixed-lineage leukemia (MLL)-
rearranged leukemia models, Liang et al. showed that IL-1 negatively
regulates the stability of wild-type but not chimeric MLL protein,
resulting in improved stability of the latter (Fig. 2D) [86]. Strikingly,
pharmacological inhibition of this signaling pathway using IL-1 recep-
tor-associated kinase (IRAK) inhibitors (Fig. 1B), remarkably delays
disease progression and improves survival in MLL-AF9+ murine
leukemia (Table 3) [86]. Future studies are required to extend these
promising mouse studies to primary human samples.
3.5. Lymphoid malignancies
A role for IL-1β has been suggested in lymphoid malignancies.
Chronic lymphocytic leukemia (CLL) is a malignancy of mature clonal B
lymphocytes that accumulate in the blood, bone marrow and other
lymphoid tissues [87]. The specific single nucleotide polymorphism
IL1B-511T, when presented in homozygosis, correlates with low risk of
CLL. Interestingly, a different single nucleotide polymorphism in IL1B
gene (IL1B-511C) together with IL6-174C, both in homozygosis,
increase to 11-fold the risk of CLL, compared to 4.5 fold increase with
IL6-174C alone [88]. This points to an association between IL-1β and
IL-6 in CLL development. Low levels of IL-1β and high levels of IL-6 are
found in the plasma of patients [88,89]. However, previous work
showed that IL-1β induces differentiation and activation of leukemic
cells in CLL patients [90]. Besides, MSCs from acute lymphocytic
leukemia (ALL) patients show increased IL-1β expression at diagnosis
[85]. Thus, future work should elucidate the potential participation of
IL-1β in lymphoid malignancies.
Table 2
2016 World Health Organization classification of myeloid neoplasms and acute leukemia.
WHO classification of myeloid neoplasm and acute leukemia classification
Myeloproliferative neoplasms (MPN)
Chronic myeloid leukemia (CML), BCR-ABL1+




PMF, overt fibrotic stage
Essential thrombocythemia (ET)
Chronic eosinophilic leukemia, not otherwise specified (NOS)
MPN, unclassifiable
Mastocytosis
Myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA,
PDGFRB, or FGFR1, or with PCM1-JAK2
Myeloid/lymphoid neoplasms with PDGFRA rearrangement
Myeloid/lymphoid neoplasms with PDGFRB rearrangement
Myeloid/lymphoid neoplasms with FGFR1 rearrangement
Provisional entity: Myeloid/lymphoid neoplasms with PCM1-JAK2
Myelodysplastic/myeloproliferative neoplasms (MDS/MPN)
Chronic myelomonocytic leukemia (CMML)
Atypical chronic myeloid leukemia (aCML), BCR-ABL1−
Juvenile myelomonocytic leukemia (JMML)
MDS/MPN with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T)
MDS/MPN, unclassifiable
Myelodysplastic syndromes (MDS)
MDS with single lineage dysplasia
MDS with ring sideroblasts (MDS-RS)
MDS-RS and single lineage dysplasia
MDS-RS and multilineage dysplasia
MDS with multilineage dysplasia
MDS with excess blasts
MDS with isolated del(5q)
MDS, unclassifiable
Provisional entity: Refractory cytopenia of childhood
Myeloid neoplasms with germ line predisposition
Acute myeloid leukemia (AML) and related neoplasms
AML with recurrent genetic abnormalities
AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1




AML with inv.(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2);GATA2, MECOM
AML (megakaryoblastic) with t(1;22)(p13.3;q13.3);RBM15-MKL1
Provisional entity: AML with BCR-ABL1
AML with mutated NPM1
AML with biallelic mutations of CEBPA
Provisional entity: AML with mutated RUNX1
AML with myelodysplasia-related changes
Therapy-related myeloid neoplasms
AML, NOS








Acute panmyelosis with myelofibrosis
Myeloid sarcoma
Myeloid proliferations related to Down syndrome
Transient abnormal myelopoiesis (TAM)
Myeloid leukemia associated with Down syndrome
Blastic plasmacytoid dendritic cell neoplasm
Acute leukemias of ambiguous lineage
Acute undifferentiated leukemia
Mixed phenotype acute leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-
ABL1





B-lymphoblastic leukemia/lymphoma with recurrent genetic abnormalities
B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2);BCR-ABL1
Table 2 (continued)
B-lymphoblastic leukemia/lymphoma with t(v;11q23.3);KMT2A rearranged
B-lymphoblastic leukemia/lymphoma with t(12;21)(p13.2;q22.1); ETV6-
RUNX1
B-lymphoblastic leukemia/lymphoma with hyperdiploidy
B-lymphoblastic leukemia/lymphoma with hypodiploidy
B-lymphoblastic leukemia/lymphoma with t(5;14)(q31.1;q32.3) IL3-IGH
B-lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3);TCF3-PBX1
Provisional entity: B-lymphoblastic leukemia/lymphoma, BCR-ABL1–like
Provisional entity: B-lymphoblastic leukemia/lymphoma with iAMP21
T-lymphoblastic leukemia/lymphoma
Provisional entity: Early T-cell precursor lymphoblastic leukemia
Provisional entity: Natural killer (NK) cell lymphoblastic leukemia/lymphoma
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4. Additional roles for IL-1β in pathophysiology: lessons from
systemic inflammatory diseases
4.1. Bone
IL-1 is a pleiotropic cytokine that exerts numerous roles in other
systems like bone, where it contributes to the fine-tuned balance
between bone resorption and formation that maintains its homeostasis.
In particular, IL-1 enhances the expression of extracellular matrix
enzymes, like collagenases that facilitate destruction of articular
cartilage [91,92]. Further, IL-1 induces differentiation of bone-resorb-
ing osteoclasts from mononuclear precursors, and has stimulating
effects on osteoclasts and resorption via TNF ligand superfamily
member 11 (RANKL) [93]. It also induces vasodilatation, promotes
attraction of granulocytes, and enhances expression of prostaglandins,
events that further help bone resorption [94].
The typical manifestation of accelerated bone remodeling is osteo-
porosis. Osteoporosis characterizes by bone thinning, damage in its
architecture and reduced mechanical strength due to diminished
mineral density. This is accompanied by high fracture risk [95]. It is
most frequent in postmenopausal women, so loss of bone mineral
density was traditionally attributed to estrogen loss [96]. More
recently, estrogens were suggested to have only minor effects [95],
and inflammatory cytokines like IL-1 were pointed out [96]. In women
who had undergone surgical menopause, increase in IL-1 secretion by
peripheral blood mononuclear cells associates with significant loss in
bone mineral density [97]. Administration of IL-1Ra improves bone
mineral density in ovariectomized rats, uncovering the therapeutic
value of targeting IL-1 against bone loss [98].
Osteoporosis and fractures are frequent in patients of systemic
inflammatory diseases, like rheumatoid arthritis [96], disease that
primarily affects synovial joints. In rheumatoid arthritis, high levels
of pro-inflammatory cytokines promote osteoclast differentiation and
bone degradation, resulting in osteoporosis [99]. High levels of IL-1
were found in the synovial membrane and fluid of patients [100,101],
while experimental models showed a major role for IL-1 in cartilage and
bone degradation [92,102,103]. This disease was the first where IL-1
antagonism was tested and proved for clinical use. Use of IL-1 inhibitors
was supported by severe arthritis development in IL-1Ra deficient mice
[104].
In osteoarthritis, IL-1 promotes cartilage degradation [105]. While
IL-1Ra prevents cartilage degeneration in animal models and improves
clinical outcomes in patients [106,107], intra-articular gene transfer of
IL-1Ra showed improved results in experimental models [108]. Re-
cently, a method was developed to produce an autologous conditioned
serum rich in IL-1Ra that seems to be an option as supplementary
therapy in patients [108,109].
4.2. Pain
IL-1 induces hyperalgesia that is increased sensitivity to pain,
through damage to nociceptors or peripheral nerves. Hyperalgesia
may affect primary afferent fibers for mechanical stimuli, resulting in
a highly disabling symptom [110]. IL-1 activates nociceptors directly
causing activation of intracellular signaling cascades, and indirectly via
production of kinins and prostanoids [111].
In certain chronic inflammatory diseases, like osteoarthritis, pain is
one of the most prominent symptoms. Studies have related IL-1 levels
with pain perception and radiographic knee lesions in patients [112].
Inflammatory stimuli, and in particular IL-1, start the cascade of events
that cause disease and drive pain in parallel [113,114]. Treatments that
reduce cartilage degeneration, reduce pain as well [106,107].
5. Clinical complications derived from hematological
malignancies
5.1. Bone morbidity
Increased inflammatory cytokines in MPN patients relate to myelo-
fibrosis at advanced stages of disease [34]. Fibrosis typically derives in
osteosclerotic lesions, particularly in PMF. PMF is a severe form of MPN
characterized by hematopoietic failure and osteosclerosis, which origi-
nates as result of growth and thickening of bone trabeculae, and new
bone formation in abnormal budding plaques [115]. PMF patients show
high levels of IL-1β in plasma [35,37], and high IL-1β levels in PV
patients predispose to fibrotic transformation [37]. Histomorphometric
measurements in 75 PMF patients showed elevated bone mineral
density compared to other forms of MPN, and correlation between
amount of bone and degree of fibrosis [116]. Surprisingly, a more
recent study using non-invasive methods in 18 patients with MF and
healthy controls matched for age, sex, and height, showed that bone
mineral density, geometry and microarchitecture in MF patients were
not significantly different [117]. Several reasons may underlie differ-
ences in results, including sample size or disease stage. Hence, future
work will be required for a better understanding of the bone disease and
a potential link to IL-1β in PMF patients.
In MPN and CML patients, epidemiological studies have concluded
increased risk of osteoporosis. For instance, a Danish study reported
increased risk of fractures among MPN patients [118]. This study
compared fracture risk among 7595 MPN patients and a cohort of
338,974 members of the general population. The fracture rates were
consistently higher at several anatomic locations including femur,
humerus, and distal forearm. The 10-year hip fracture risk was 7% in
ET patients and 9% in PV patients, with a risk of 5% among matched
controls. Interestingly, the same study showed risk of hip fracture 2.7-
fold higher in CML patients than in the general population [118]. CML
patients were stratified according to presence or absence of tyrosine
kinase inhibitor treatment. Treatment turns CML into a more chronic
condition with longer life expectancy, and reduces the need for
allogeneic bone marrow transplantation [119]. However, it does not
influence the fracture risk in CML patients [118]. In another study
performed on 36 CML patients, skeletal lesions were examined by x-ray.
Lesions were positive in 16% of the cases, and included osteoporosis,
osteolytic and osteoblastic lesions, and chloromas, i.e. myeloid sarco-
mas outside of the bone marrow [120]. Further, osteoporosis and
vertebral fracture are frequent in patients with systemic mastocytosis
with respectively 31 and 17% in a cohort of 75 patients [121].
Nevertheless, the direct contribution of chronic inflammation and IL-
1 to bone loss specifically in myeloid leukemias remains unknown, and
should be subject of future investigation (Table 4).
Table 3
Summary of treatments targeting IL-1 pathway efficient in mouse models of hematological malignancies.
Hematological malignancy Preclinical model Drug Mechanism Reference
MPN JAK2-V617F IL-1Ra IL-1Ra is a competitive inhibitor of α and IL-1β signaling that binds to IL-1R1
impeding its interaction with the cytokines
[39]
CML BCR-ABL IL-1Ra and Imatinib [60]
JMML Ptpn11-E76K in MSPCs CCR1a or CCR5a Antagonists that block CCL3 binding to CCR1 or CCR5, respectively [65]
AML MLL-AF9 IRAK1/4 or IRAK4
inhibitors
Inhibition of IL-1R-associated kinases that impedes signaling downstream IL-1R1 [86]
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Bone morbidity seems to be present in other types of hematological
malignancies like ALL (Table 4). ALL is the most common leukemia in
childhood, and induces significant effects on the skeleton of children
and adolescents that show, at the moment of diagnosis, lower bone
density than their healthy counterparts [122]. Low bone turnover status
explains through reduced bone formation but normal resorption
markers [123]. Further, ALL patients have increased fracture rate
compared to healthy controls [124], and fracture risk is higher in
ALL survivors after the end of the treatment [125,126]. However, little
is known about the molecular mechanisms driving bone complications
in ALL patients.
5.2. Hematopoietic malignancies and pain
Interestingly, the most important hematopoietic disease-related
pain affects bone, and it was traditionally related to osteolytic lesions
and infiltration of bone marrow with malignant cells. In the context of
hematopoietic disorders, pain may be correlated to disease and its
complications, or to diagnostic procedures and treatments [127]. When
pain is present at disease onset, treatment with chemotherapeutic
agents or other therapies usually drive pain relief. This is frequent in
ALL patients [128].
Our recent work may provide hints linking pathogenesis and pain in
hematopoietic malignancies. Particularly in experimental models of
MPN, we showed that mutant cells produce IL-1β that damages the
neuroglial components in the bone marrow at early stages of the
disorder. Schwann cells, that cover and protect the integrity of the
peripheral neural fiber, are rapidly reduced in the disease bone marrow.
Sympathetic fibers are subsequently injured, in both disease mice and
humans, which may contribute to bone pain reported in MPN patients
[129]. Reduction in sympathetic regulation together with IL-1β stimu-
lation results eventually in expansion of mutant cells, that is amelio-
rated by treatment with IL-1Ra in vivo [39]. Hence, IL-1 may be
pathogenic factor and pain driver in MPN, and represents a good
candidate for clinical interventions.
Additionally, both ALL and AML survivors may experience chronic
pain due to complications associated to hematopoietic cell transplanta-
tion [130]. Pain origin after transplantation seems to relate to injury to
mucosal tissues induced by the conditioning regimen, like chemother-
apy [131]. In mouse models and clinical settings, cisplatin, that is a
common chemotherapy, induces sensory neuropathy [132,133].
Further, experimental models demonstrated cisplatin-induced bone
marrow nerve injury that impairs hematopoietic regeneration and
could thereby compromise success of the transplant [132]. To date,
the molecular mechanisms driving neural damage after chemotherapy
have not been thoroughly defined.
6. Hematopoietic malignancies and autoimmune diseases
The connection between autoimmune diseases and hematopoietic
malignancies goes beyond common bone affectation and pain. Actually,
a number of epidemiological studies show higher risk of hematopoietic
malignancies in patients with autoimmune diseases compared to the
general population, with further increase after cytotoxic treatment
[134]. Interestingly, autoimmune disease patients with secondary acute
leukemia usually develop AML rather than ALL [135]. History of any
autoimmune disease has been associated with increased risk of AML
and MDS [1,136]. In particular, AML risk is significantly associated
with rheumatoid arthritis, systemic lupus erythematosus, polymyalgia
rheumatica, autoimmune hemolytic anemia, systemic vasculitis, perni-
cious anemia, and inflammatory bowel disease like ulcerative colitis
and Crohn's disease [134,136,137]. Additionally, systemic mastocytosis
is related to higher prevalence of inflammatory joint diseases like
spondyloarthritis and rheumatoid arthritis [138,139]. Interestingly, the
clinical appearance of non-Hodgkin's lymphoma and systemic lupus
erythematosus is similar, making them difficult to distinguish at early
stages. This raises the possibility that systemic lupus erythematosus
may be a paraneoplastic syndrome and appears on the grounds of the
hematopoietic malignancy [140]. Conversely, a hematopoietic disorder
may precede the autoimmune disease, and for instance early manifesta-
tion of an occult malignancy may be fast development of rheumatoid
arthritis-like syndromes [141].
Additionally, increased risk of AML is associated to an autoimmune
disease of the central nervous system: multiple sclerosis. Multiple
sclerosis develops as consequence of autoimmune demyelination of
the central nervous system leading to progressive disability.
Immunomodulatory drugs like IFN-β are used as first-line therapy,
and non-responsive patients are treated with strong immunosuppressive
and cytotoxic drugs like mitoxantrone [142]. Multiple sclerosis patients
treated with mitoxantrone are at particularly high risk of developing
AML. However, not all patients exposed to this drug develop AML,
whereas others do without mitoxantrone treatment [143,144].
The factors predisposing to AML in autoimmune diseases are
currently subject of extensive research. Defective immune system and,
as previously mentioned, immunosuppressive therapies seem to be risk
factors that allow tumor progression [145,146]. Mutations in certain
genes are shared by both autoimmune diseases and cancer, including
the tumor suppressor p53, the death receptor Fas, and the signaling
pathway phosphatidylinositol 3-kinase/protein kinase B/mammalian
Target Of Rapamycin, among others [147–151]. Further, inflammation
is a common event within both pathogenic processes. Inflammation
enhances tumor progression through complex inflammatory signaling
cascades that involve NF-κB activation, related to both leukemia and
autoimmune diseases like rheumatoid arthritis [152–154]. Importantly,
it is well-described that activated NF-κB induces transcription of proIL-
1β.
As discussed in the previous sections, IL-1 and specifically IL-1β
plays a pathogenic role in a variety of hematopoietic malignancies,
particularly those involving the myeloid lineage. This statement holds
true for a wide range of systemic inflammatory and autoimmune
diseases [155]. In both hematopoietic malignancies and autoimmune
diseases, there is a link to bone and pain complications. Hence, it is
reasonable to hypothesize that IL-1 may underlie morbidity and may as
well provide a link between hematopoietic malignancies and autoim-
mune diseases. Future work is required to validate this hypothesis. If IL-
1 participates in pathogenesis, complications and second disease in
both hematopoietic malignancies and autoimmune diseases, fine-tuned
management of IL-1 levels would have utility in numerous disorders
and substantially improve quality of life in patients.
7. FDA-approved therapeutic strategies for IL-1 blockade
Extensive clinical research is being performed with a variety of
agents that reduce IL-1 activity. Currently, these drugs include IL-1Ra,
soluble receptors, antibodies, and IL-1 traps among others. Some of
these drugs are being actively pursued at Phases I to III in clinical trials
to treat a broad spectrum of diseases [155–158]. In spite of their
therapeutic potential, so far few studies have evaluated their effects
against different types of cancer and hematological malignancies. One
example of the latter is MABp1, naturally occurring monoclonal anti-
body that neutralizes IL-1α. In 2012, a Phase I clinical study was
Table 4
Summary of clinical data in hematological malignancies where both increased IL-1β and
bone morbidity are present in patients.
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completed with patients of advanced hematological malignancies
(NCT01260545), but its results are not published yet. One prevailing
presumption for this little interest is that IL-1 blockade may be
contraindicated for patients as it may further promote cancer-related
immunosuppression [158]. However, this theory may be misinterpreted
[159], given that IL-1 neutralization reduces the inflammation that
contributes to cancer-related immunosuppression [160]. Future studies
are required to further clarify this perspective. As of today, the
following therapeutic opportunities targeting IL-1 are FDA-approved:
anakinra, rilanocept and canakinumab.
7.1. Anakinra (Kineret)
Anakinra is the recombinant form of the naturally occurring IL-1Ra,
it exerts its function blocking the IL-1 receptor and thus reduces the
activity of both IL-1α and IL-1β. Anakinra was FDA-approved in 2001
to treat rheumatoid arthritis, and since then it has been proved as an
efficient and safe therapy in a variety of diseases [156]. It is currently
being tested in numerous clinical trials. A Phase II study in patients with
smoldering or indolent multiple myeloma (NCT00635154), who were
at risk of progression to active myeloma, tested the ability of anakinra
to delay or prevent active myeloma. Between November 19, 2002, and
May 24, 2007, 47 patients were enrolled in the study and treated with
anakinra [161]. In 25 (53%) of the patients, low-dose dexamethasone
was administered in addition. Treatment with anakinra alone lead to a
minor response in 3 patients, a partial response in 5 patients and a
minor response after addition of dexamethasone in 4 patients. In those
who responded, anakinra decreased high-sensitivity C-reactive protein
(hs-CRP) levels and myeloma proliferative rate, which correlated with
prolonged chronic disease state and improved progression-free survival
[161]. A Phase I/II clinical study (NCT02492750) is currently recruit-
ing participants for treatment of early stage multiple myeloma patients
with lenalidomide and dexamethasone with or without anakinra.
Intravenous administration is preferred considering its safety even
at blood levels 100-fold higher than those achieved following sub-
cutaneous injection [156]. In addition, one important limitation of
anakinra is its relatively short half-life of 4 to 6 h [155], leading to drop
in blood levels within hours after injection [156]. Evidence from
preclinical models of disease indicates that the therapeutic effectiveness
of IL-1Ra is crucially dependent on optimal level of dosing for
continuous saturation of IL-1 receptors [162]. Hence, anakinra may
not allow adequate evaluation of the efficiency of anti-IL-1 treatments,
given that partial reactivation of inflammation may occur during 24-
hour dosage.
7.2. Rilanocept (Arcalyst)
Rilonacept, also known as IL-1 trap, is a soluble decoy receptor
comprising the human IL-1 receptor 1 (extracellular domain and
accessory protein) and the Fc portion of human IgG1 [163]. This
recombinant fusion protein neutralizes both free IL-α and IL-β with
high affinity [155]. Rilonacept was approved by FDA in 2008 for the
treatment of cryopyrin-associated periodic syndromes, a group of
diseases caused by inherited mutations on the genes CIAS1 or NLRP3,
encoding cryopyrin or NALP3, respectively, which result in sponta-
neous assembly of the inflammasome with caspase 1 over-activation
and IL-1β secretion [164]. A number of clinical trials are currently
being developed to use rilanocept against a variety of diseases,
including type 1 diabetes (NCT00962026), atherosclerosis
(NCT00417417), hepatitis (NCT01903798) and chronic kidney disease
(NCT01663103). However, none of these studies involve patients of
hematological malignancies.
In addition to its high affinity binding IL-α and IL-β, rilonacept has
been proved as a safe and well-tolerated therapy [155,165,166]. When
compared to anakinra, rilonacept shows an extended circulation half-
life in vivo of 8.6 days, and thus it is administered in patients as a
weekly subcutaneous injection [166]. Further, both in vitro and in vivo
studies showed that IL-1 trap is more efficient than IL-1Ra [165,167]. In
mice, IL-1 trap injected subcutaneously 24 h prior to IL-1β injection was
able to fully block IL-1-induced inflammation. This single dose of IL-1
trap also blocked the effect of a second IL-1β injection, 24 h later. In
contrast, IL-1Ra did not inhibit IL-1-induced inflammatory response at a
dose 15-fold higher than that of IL-1 trap [167]. Thus, on-going and
future clinical trials with IL-1 trap should help us determine accurately
the promising therapeutic value of IL-1 blockade in multiple diseases
including hematological malignancies.
7.3. Canakinumab (Ilaris)
The most recent approach is canakinumab, a monoclonal antibody
that specifically neutralizes human IL-1β and was produced in a
transgenic mouse strain. It binds to human IL-1β with high affinity
and specificity, and the complex formed with the cytokine is unable to
attach to the receptor, thereby blocking IL-1β dependent signaling
[168,169]. Canakinumab was FDA-approved in 2009 for the treatment
of cryopyrin-associated periodic syndromes [170]. Currently, numerous
clinical trials are being performed, to treat a broad spectrum of diseases
like osteoarthritis (NCT01160822), chronic obstructive pulmonary
disease (NCT00581945), type 2 diabetes (NCT00605475), atherosclero-
sis (NCT00995930) and rheumatoid arthritis (NCT00504595,
NCT00424346). So far, however, no clinical trial has been registered
that considers patients of hematological malignancies.
Its high affinity and specificity have been proven both in vitro and in
vivo. While it does not interfere with IL-1α signaling [170], canakinu-
mab fully blocks IL-β-induced inflammation and cartilage destruction in
mouse models of arthritis [168,171]. In patients, it can be administered
intravenously or subcutaneously. The maximum blood concentration is
found after 7 days of a single subcutaneous dose, and its half-life is
26 days [168,170,172]. This is a substantial advantage over anakinra
and rilonacept, given that canakinumab is administered bimonthly, as
opposed to the weekly or daily injections with rilonacept or anakinra,
respectively [173]. It is well tolerated in patients, and no severe adverse
effects have been reported. Its use is approved in children [170]. IL-1β
neutralization will allow to see if IL-1β is indeed a crucial mediator of
numerous diseases, and its targeting may serve as therapy or coadju-
vant treatment in hematological malignancies and their related com-
plications.
8. Summary and future directions
IL-1 is a pleiotropic cytokine that exerts numerous roles in both
physiological and pathological conditions. It is produced by a variety of
cells, and elicits a wide range of inflammatory responses in a number of
cell subsets. Dysregulated IL-1 seems to be essential in many human
diseases, including hematopoietic malignancies and autoimmune dis-
eases, their complications, and may be their connection. Hence, drugs
that target IL-1 may be helpful in numerous inflammatory conditions
and have shown promising therapeutic value in experimental models of
hematological malignancies. Currently, these drugs include IL-1Ra,
soluble receptors, antibodies, and IL-1 traps among others. Some of
these agents are FDA-approved, and used safely and efficiently as
therapy against autoimmune diseases like rheumatoid arthritis.
In the clinical setting, however, IL-1Ra seems to be limited by its
biological and pharmacokinetic properties [155]. Likely, this has
prevented the full potential of IL-1 targeting to be tested in patients.
IL-1 trap is more efficient and has extended half-life in vivo [165,166].
The drug rilonacept is a fusion protein comprising the human IL-1
receptor 1 (extracellular domain and accessory protein) and the Fc
portion of human IgG1 [163]. Further, the monoclonal antibody
canakinumab neutralizes IL-1β specifically, and has even more pro-
longed half-life [168,170,172]. These next generation of drugs with
improved chemical, pharmacological and biological properties, should
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allow us to determine accurately the promising therapeutic value of IL-
1 and in particular IL-1β in multiple hematological malignancies and
their related complications.
Practice points
− High IL-1β signaling is present in patients of hematological malig-
nancies, in particular those with myeloid component.
− Recent preclinical studies demonstrate the pathogenic role of IL-1β
in hematological malignancies.
− Targeting of IL-1β pathway shows great therapeutic potential in
mouse models.
− IL-1β is responsible for bone degeneration and pain in systemic
inflammatory diseases.
− IL-1β is a good candidate promoting morbidity in patients, by
linking to bone complications, pain and second disease.
Research agenda
− Clinical trials with patients of hematological diseases, combining
specific treatments with targeting of IL-1 pathway.
− Test rilanocept and canakinumab in mouse models of hematological
malignancies.
− Further development of drugs with improved properties and test in
preclinical mouse models.
− Use of mouse models of hematological malignancies to investigate
the causative role of IL-1β in complications and autoimmune
disease.
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